Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14638858 | 0.81 | LOX (0.59) | POLBSMN1; SMN2CTDSP1TDP1ALDH1A1 | |
| SCHEMBL13605711 | 0.80 | TSHR (0.71) | POLBSMN1; SMN2TDP1ALDH1A1HPGD | |
| SCHEMBL14638937 | 0.80 | POLB (0.50) | POLBSMN1; SMN2CTDSP1TDP1ALDH1A1 | |
| SCHEMBL14638939 | 0.80 | KMT2A (0.73) | POLBSMN1; SMN2CTDSP1TDP1ALDH1A1 | |
| SCHEMBL24667209 | 0.76 | POLB (0.53) | POLBSMN1; SMN2CTDSP1TDP1ALDH1A1 | |
| SCHEMBL7475601 | 0.75 | DDIT3 (0.57) | POLBSMN1; SMN2CTDSP1TDP1ALDH1A1 | |
| SCHEMBL1062277 | 0.74 | ALDH1A1 (0.48) | POLBSMN1; SMN2CTDSP1TDP1ALDH1A1 | |
| SCHEMBL6370226 | 0.74 | POLB (0.58) | POLBSMN1; SMN2CTDSP1TDP1ALDH1A1 | |
| SCHEMBL14507368 | 0.73 | SMN1; SMN2 (0.47) | POLBSMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL24667211 | 0.72 | LMNA (0.57) | POLBSMN1; SMN2CTDSP1TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495683-B2 | HERPES VIRUS | PHARMACIA AND UPJOHN COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1159279-B1 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | disclosed |
| EP-1159279-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6239142-B1 | HERPES VIRUS INFECTION | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000053610-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | IRF3, IL4, ZC3HAV1 | GCK 351/4885POLB 751/4885SMN1; SMN2 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.